When mice are exposed to harmless objects such as marbles in their cage they bury them, a behaviour sometimes known as defensive burying. We investigated the effect of an acute dose of MDMA (èecstasy') and other psychoactive drugs on marble burying and also examined the effect of a prior neurotoxic dose of MDMA or p-chloroamphetamine (PCA) on burying. Acute administration of MDMA produced dose-dependent inhibition of marble burying (EC50: 7.6 µ mol/kg). Other drugs that enhance monoamine function also produced dose-dependent inhibition: methamphetamine 〉 PCA 〉 paroxetine 〉 MDMA 〉 GBR 12909 〉 methylphenidate. None of these drugs altered locomotor activity at a dose that inhibited burying. A prior neurotoxic dose of MDMA, which decreased striatal dopamine content by 60%, but left striatal 5-HT content unaltered, did not alter spontaneous marble burying 18 or 40 days later. However, a neurotoxic dose of PCA which decreased striatal dopamine by 60% and striatal 5-HT by 70% attenuated marble burying 28 days later. Overall, these data suggest that MDMA, primarily by acutely increasing 5-HT function, acts like several anxiolytic drugs in this behavioural model. Long-term loss of cerebral 5-HT content also produced a similar effect. Since this change was observed only after 28 days, it is probably due to an adaptive response in the brain.
Baldwin H A, Colado M I, Murray T K, De Souza R J, Green A R (1993) Striatal dopamine release in vivofollowing neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br J Pharmacol108: 590–596
2.
Bhattacharya S K, Bhattacharya A, Ghosal S (1998) Anxiogenic activity of methylenedioxymethamphetamine (ecstasy). An experimental study. Biogenic Amines14: 217–237
3.
Briley M, Chopin P, Moret C (1990) Effect of serotonergic lesion on ‘anxious’ behaviour measured in the elevated plus-maze test in the rat. Psychopharmacology101: 187–189
4.
Broekkamp C L, Rijk H W, Joly-Gelouin D, Lloyd K L (1986) Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming mice. Eur J Pharmacol126: 223–229
5.
Camarero J, Sanchez V, O'shea E, Green A R, Colado M I, (2002) Studies, using in vivomicrodialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine (‘ecstasy’)-induced dopamine release and free radical formation in the mouse striatum. J Neurochem81: 961–971
6.
Colado M I, O'shea E, Green A R (2004) Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology173: 249–263
7.
Colado M I, O'shea E, Granados R, Murray T K, Green A R (1997) In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA (‘ecstasy’) and pchloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol12: 889–900
8.
Colado M I, O'shea E, Granados R, Esteban B, Martin A B, Green A R (1999) Studies on the role of dopamine in the degeneration of 5-HT nerve endings in Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration. Br J Pharmacol126: 911–924
9.
Colado M I, Camarero J, Mechan A O, Sanchez V, Esteban B, Elliott J M, Green A R (2001) A study of the mechanisms involved in the neurotoxic action of 3,4-methylenesioxymethamphetamine (MDMA, ‘ecstasy’) on dopamine neurones in mouse brain. Br J Phamracol134: 1711–1723
10.
Curran H V, Travill R A (1997) Mood and cognitive effects of ±-3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’): week-end ‘high’ followed by mid-week low. Addiction92: 821–831
11.
Davison D, Parrott A C (1997) Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Human Psychopharmacol12: 221–226
12.
De Boer S F, Koolhaas J M (2003) Defensive burying in rodents: ethology, neurobiology and psychopharmacology. Eur J Pharmacol463: 145–161
13.
de Win M M L, Reneman L, Reitsma J B, den Heeten G J, Booij J, van den Brink W (2004) Mood disorders and serotonin transporter density in ecstasy users – the influence of long term abstention, dose, and gender. Psychopharmacology173: 376–382
14.
Farré M, de la Torre R, Mathúna B ”, Roset P N, Peiró A M, Torrens M, Ortuño J, Pujadas M, Camí J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokineticsPsychopharmacology173: 364–375
15.
Fone K C F, Beckett S R G, Topham I A, Swettenham J, Ball M, Maddocks L (2002) Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology159: 437–444
16.
Gamma A, Frei E, Lehmann D, Pascual-Marqui R D, Hell D, Vollenweider F X (2000) Mood state and brain electric activity in ecstasy users. NeuroReport11: 157–162
17.
Gianutsos G, Lal H (1975) Aggression in mice after p-chloroamphetamine. Res Commun Chem Pathol Pharmacol10: 379–382
18.
Gordon C J, Wilkinson W P, O'Callaghan J P, Miller D B (1991) Effect of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav38: 339–344
19.
Green A R, McGregor I S (2002) On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. Psychopharmacology164: 448–450
20.
Green A R, Mechan A O, Elliott J M, O'shea E, Colado M I (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). Pharmacol Revs55: 463–508
21.
Gurtman C G, Morley K C, Li K M, Hunt G E, McGregor I S (2002) Increased anxiety in rats after 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): association with serotonin depletion. Eur J Pharmacol446: 89–96
22.
Harris D S, Baggott M, Mendleson J H, Mendleson J E, Jones R T (2002) Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology162: 396–405
23.
Iversen S D (1984) 5-HT and anxiety. Neuropharmacology23: 1553–1560
24.
Iyer R N, Sprouse J S, Aghajanian G K, Roth R H, Bradberry C W (1994) Tryptophan pre-treatment augmentation of pchloroamphetamineinduced serotonin and dopamine release and reduction of long-term neurotoxicity. Biochem Pharmacol48: 1501–1508
25.
Kuczenski R, Segal D S (1997) Effects of methylphenidate on extracellular dopamine, serotonin and norepinephrine: Comparison with amphetamine. J Neurochem68: 2032–2037
26.
Leonard B E, McCartan D, White J, King D J (2004) Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Human Psychopharmacol19: 151–180
27.
Lin H Q, Burden P M, Christie M J, Johnston G A R (1999) The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharmacol Biochem Behav62: 403–408
28.
Logan B J, Laverty R, Sanderson W D, Yee Y B (1988) Differences between rats and mice in MDMA (methylenedioxymethamphetamine) neurotoxicity. Eur J Pharmacol152: 227–234
29.
McCardle K, Luebbers S, Carter J D, Croft R J, Stough C (2004) Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology173: 434–439
30.
McGregor I S, Clemens K J, Van der Plasse G, Li K M, Hunt G E, Chen F, Lawrence A J (2003) Increased anxiety 3 months after brief exposure to MDMA (‘Ecstasy’) in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology28: 1472–1484
31.
Maldonado E, Navarro J F (2001) MDMA (‘Ecstasy’) exhibits an anxiogenic-like activity in social encounters between male mice. Pharmacol Res44: 27–31
32.
Martin J R, Bös M, Jenck F, Moreau J-L, Mutel V, Sleight A J, Wichmann J, Andrews J S, Berendsen H H G, Broekkamp C L E, Ruigt G S F, Köhler C, van Delft A M L (1998) 5-HT2C receptor agonists: Pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther286: 913–924
33.
Mechan A O, Moran P M, Elliott J M, Young A M J, Joseph M H, Green A R (2002a) A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and their response to diazepam. Psychopharmacology159: 188–195
34.
Mechan A O, Moran P M, Elliott J M, Young A M J, Joseph M H, Green A R (2002b) A study of the effects of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) on the subsequent long-term behaviour of rats in the plus maze and open field. Psychopharmacology159: 167–175
35.
Millan M J, Girardon S, Mullot J, Brocco M, Dekeyne A (2002) Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 (NK1) receptor antagonists. Neuropharmacology42: 677–684
36.
Millan M J, Dekeyne A, Papp M, La Rochelle C R, Macsweeny C, Peglion J-L, Brocco M (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram and clomipramine. J Pharmacol Exp Ther298: 581–591
37.
Morgan M J (1998) Recreactional use of ecstasy (MDMA) is associated with increased impulsivity. Neuropsychopharmacology19: 252–264
38.
Morley K C, McGregor I S (2000) (±)3,4-Methylenedioxymethamphetamine (MDMA, ‘ecstasy’) increases social interaction in rats. Eur J Pharmacol408: 41–49
39.
Morley K C, Gallate J E, Hunt G E, Mallet P E, McGregor I S (2001) Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine (‘Ecstasy’). Eur J Pharmacol433: 91–99
40.
Nash J F, Meltzer H Y, Gudelsky G A (1988) Elevation of serum prolactin and corticosterone concentrations after administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther245: 873–879
41.
Nichols D E (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs18: 305–313
42.
Njung'e K, Handley S L (1991a) Evaluation of marble-burying behaviour as a model of anxiety. Pharmacol Biochem Behav38: 63–67
43.
Njung'e K, Handley S L (1991b) Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol104: 105–112
44.
O'shea E, Esteban B, Camarero J, Green A R, Colado M I (2001) Effect of GBR 12909 and fluoxetine on the acute and long-term changes induced by MDMA (‘ecstasy’) on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology40: 65–71
45.
Parrott A C, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology139: 261–268
46.
Parrott A C, Sisk E, Turner J D (2000) Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug Alcohol Depend60: 105–110
47.
Parrott A C, Milani R M, Parmar R, Turner J J D (2001) Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology159: 77–82
48.
Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra M G, de Wolff F A, Booij J (2002) The acute and chronic effects of MDMA (‘Ecstasy’) on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology26: 387–396
49.
Roiser J P, Sahakian B J (2004) Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology173: 411–417
50.
Sharp T, Zetterström T, Christmanson L, Ungerstedt U (1986) p-Chloroamphetamine releases both serotonin and dopamine into rat brain dialysates in vivo. Neurosci Letts72: 320–324
51.
Sugita R, Terada K, Sekiya Y, Sawa Y, Nomura S, Nakazawa T (1994) Effect of p-chloroamphetamine administration on monoamine metabolism in the rat nucleus accumbens and locomotor activity: studies with intracerebral dialysis in freely moving rats. Brain Res658: 255–258
52.
Tye N C, Everitt B J, Iversen S D (1977) 5-hydroxytryptamine and punishment. Nature268: 741–743
53.
Tye N C, Iversen S D, Green A R (1979) The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology18: 689–695
